Table 2.
Baseline Clinical and Immunological Characteristics with INH Status of Study Participants in Northwest Ethiopia from September 11, 2008 to March, 2015, N = 391
| Clinical Variables | Sub Category | INH (%) | Never on INH (%) |
|---|---|---|---|
| WHO stage | Stage I | 63(32.6) | 58(29.3) |
| Stage II | 45(23.3) | 49(24.7) | |
| Stage III | 80(41.5) | 78(39.4) | |
| Stage IV | 5(2.6) | 13(6.6) | |
| Previous TB rx. | Yes | 23(11.9) | 22(11.1) |
| No | 170(88.1) | 176(88.9) | |
| B. functional stat. | Working | 155(80.3) | 157(79.3) |
| Ambula.&B | 38(19.7) | 41(20.7) | |
| Baseline BMI | <18.5 kg/m2 | 64(33.2) | 87(43.9) |
| ≥18.5 kg/m2 | 129(66.8) | 111(56.1) | |
| Baseline Hgb. | <10 mg/dl | 5(2.6) | 9(4.5) |
| 10–12 mg/dl | 26(13.5) | 43(21.7) | |
| >12 mg/dl | 162(83.9) | 146(73.7) | |
| Baseline CD4 | ≤100 cells/μL | 35(18.1) | 46(23.2) |
| 101–200 cells/μL | 49(25.4) | 57(28.8) | |
| 201–350 cells/μL | 50(25.9) | 47(23.7) | |
| >350 cells/μL | 59(30.6) | 48(24.2) | |
| CD4 at ART initiat. | ≤100 cells/μL | 35(20.3) | 37(22.6) |
| 101–200 cells/μL | 68(39.5) | 61(37.2) | |
| 201–350 cells/μL | 51(29.7) | 39(23.8) | |
| >350 cells/μL | 18(10.5) | 27(16.5) | |
| ART status | On ART | 172(89.1) | 164(82.8) |
| On Pre-ART | 21(10.9) | 34(17.2) | |
| Past OIs than TB | Yes | 80(41.5) | 96(48.5) |
| No | 113(58.5) | 102(51.5) | |
| CPT initiation | Yes | 167(86.5) | 169(85.4) |
| No | 26(13.5) | 29(14.6) |
Abbreviations: ART initiat, ART initiation; previous TB rx, previous TB treatment history; functional stat, functional status.